With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. The immuno-oncology outfit is weighing a full range of strategic options, including selling or merging the company, with the goal of giving shareholders the biggest bang for their buck.


